Parkinson’s Disease: Alpha Synuclein, Heme Oxygenase and Biotherapeutic Countermeasures

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|24|20|2317-2321

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.24, Iss.20, 2018-06, pp. : 2317-2321

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

-Synuclein Ubiquitination and Novel Therapeutic Targets for Parkinson’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 4, 2014-06 ,pp. : 630-637

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Alpha-Synuclein for the Treatment of Parkinson’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 2, 2012-03 ,pp. : 174-179

Bentham Science Publishers

Access to resources Recommend Favorite

Heme Oxygenase-1 in Lung Disease

By  

Current Drug Targets, Vol. 11, Iss. 12, 2010-01 ,pp. : 1532-1540

Bentham Science Publishers

Access to resources Recommend Favorite

Heme Oxygenase and the Skin in Health and Disease

By  

Current Pharmaceutical Design, Vol. 24, Iss. 20, 2018-06 ,pp. : 2303-2310

Bentham Science Publishers

Access to resources Recommend Favorite

Entacapone in the management of Parkinson’s disease

By Waters Cheryl   Henchcliffe Claire  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 957-963

Informa Healthcare

Access to resources Recommend Favorite